Postremissional rituximab administration for the treatment of older chronic lymphocytic leukemia (CLL) patients responsive to first line therapy with chlorambucil and prednisone.

被引：0
|
作者：
Mauro, FR [1 ]
Gentile, M [1 ]
De Propris, MS [1 ]
Giammartini, E [1 ]
Buffolino, S [1 ]
Ghia, M [1 ]
Paoloni, F [1 ]
Valle, V [1 ]
Guarini, AR [1 ]
Alimena, G [1 ]
Mandelli, F [1 ]
Foa, R [1 ]
机构：
[1] Univ Roma La Sapienza, Cellular Biotecnol & Hematol Dept, Rome, Italy
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2497
引用
收藏
页码：674A / 674A
页数：1
相关论文
共 50 条
  • [21] Role of rituximab in first-line treatment of chronic lymphocytic leukemia
    Bryan, Jeffrey
    Borthakur, Gautam
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 1 - 11
  • [22] BENDAMUSTINE IN COMBINATION WITH RITUXIMAB AS FIRST LINE THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A RETROSPECTIVE REAL PRACTICE ITALIAN MULTICENTRE STUDY
    Gentile, M.
    Ciolli, S.
    Molica, S.
    Di Renzo, N.
    Selleri, C.
    Villa, M. R.
    De Paolis, M. R.
    Scortechini, I.
    Giannotta, A.
    Minoia, C.
    Boncompagni, R.
    Bonanno, V.
    Levato, L.
    Musso, M.
    Mastrullo, L.
    Melpignano, A.
    Murru, R.
    Angelucci, E.
    Caparrotti, G.
    Guarini, A.
    Pinto, A.
    Ferrara, F.
    Zinzani, P.
    Morabito, F.
    HAEMATOLOGICA, 2014, 99 : 584 - 584
  • [23] Chronic Lymphocytic Leukemia (CLL) The choice of a BTKl in first and second line therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [24] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [25] First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Patients With Obinutuzumab Based Therapy: Single-Center Experience
    Trajkova, Sanja
    Pivkova-Veljanovska, Aleksandra
    Krstevska-Balkanov, Svetlana
    Popova-Labacevska, Marija
    Ridova, Nevenka
    Stojanovska-Jakimovska, Simona
    Cvetanovski, Milche
    Chadievski, Lazar
    Kocoski, Bozidar
    Panovska-Stavridis, Irina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S326 - S326
  • [26] CHLORAMBUCIL FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - SYSTEMATIC REVIEW AND META-ANALYSIS
    Vidal, L.
    Gurion, R.
    Gafter-Gvili, A.
    Raanani, P.
    Bairy, O.
    Robak, T.
    Shpilberg, O.
    HAEMATOLOGICA, 2012, 97 : 57 - 57
  • [27] Sequential Treatment With Bendamustine, Rituximab, Chlorambucil and Fludarabine Leads To a Major Survival Improvement Of Patients With Chronic Lymphocytic Leukemia (CLL) In Routine Care
    Weide, Rudolf
    Feiten, Stefan
    Friesenhahn, Vera
    Heymanns, Jochen
    Kleboth, Kristina
    Thomalla, Joerg
    van Roye, Christoph
    Koeppler, Hubert
    BLOOD, 2013, 122 (21)
  • [28] Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study
    Hillmen, Peter
    Gribben, John G.
    Follows, George A.
    Milligan, Donald
    Sayala, Hazem A.
    Moreton, Paul
    Oscier, David G.
    Dearden, Claire E.
    Kennedy, Daniel B.
    Pettitt, Andrew R.
    Nathwani, Amit
    Varghese, Abraham
    Cohen, Dena
    Rawstron, Andy
    Oertel, Stephan
    Pocock, Christopher F. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1236 - +
  • [29] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Hainsworth, John D.
    Vazquez, Elizabeth R.
    Spigel, David R.
    Raefsky, Eric
    Bearden, James D.
    Saez, Ruben A.
    Greco, F. Anthony
    CANCER, 2008, 112 (06) : 1288 - 1295
  • [30] Rituximab® and high dose methylprednisolone (HDMP) as a first line treatment for patients with chronic lymphocytic leukemia
    Castro, JE
    Bole, JE
    Prada, CE
    Loria, O
    Kipps, TJ
    BLOOD, 2005, 106 (11) : 833A - 833A
12345